Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
复制标题
DOI：
10.1182/blood-2010-02-270785
复制
发表时间：
2010-11-04
期刊：
影响因子：
20.3
通讯作者：
Pfreundschuh, Michael
中科院分区：
文献类型：
--
作者：
Schmitz, Norbert;Truemper, Lorenz;Pfreundschuh, Michael
为了评估T细胞淋巴瘤患者的预后，我们分析了德国高级别非霍奇金淋巴瘤研究小组(DSHNHL)试验中治疗的343例患者。289例患者属于4种主要T细胞淋巴瘤亚型中的一种：间变性大细胞淋巴瘤、间变性大细胞淋巴瘤激酶阳性(n=78)、间变性大细胞淋巴瘤(ALK)阴性(n=113)、外周T细胞淋巴瘤(PTCLU)(n=70)和血管免疫母细胞T细胞淋巴瘤(AITL)(n=28)。治疗包括6-8个疗程的CHOP(环磷酰胺、阿霉素、长春新碱、强的松/强的松龙)或依托泊苷(CHOEP)。ALK阳性组3年无事件生存率和总生存率分别为75.8%和89.8%，AITL组分别为50.0%和67.5%，ALK阴性组分别为45.7%和62.1%，PTCLU组分别为41.1%和53.9%。国际预后指数(IPI)在定义结果有显著差异的风险组方面是有效的。对于患者，1例预后较差，应考虑采用新的治疗策略。(血。2010；116(18)：3418-3425)
To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Two hundred eighty-nine patients belonged to 1 of the 4 major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), anaplastic large cell lymphoma kinase (ALK)-positive (n = 78); ALCL, ALK-negative (n = 113); peripheral T-cell lymphoma, unspecified (PTCLU; n = 70); and angioimmunoblastic T-cell lymphoma (AITL; n = 28). Treatment consisted of 6-8 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) or etoposide plus (CHOEP). Three-year event-free survival (EFS) and overall survival were 75.8% and 89.8% (ALK-positive ALCL), 50.0% and 67.5% (AITL), 45.7% and 62.1% (ALK-negative ALCL), and 41.1% and 53.9% (PTCLU), respectively. The International Prognostic Index (IPI) was effective in defining risk groups with significantly different out-comes. For patients, 1 have a poor prognosis and should be considered candidates for novel treatment strategies. (Blood. 2010;116(18):3418-3425)